 |
 |
|
|
RESÚMENES MARZO 2006 |
Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal
para acceder al resúmen)
Perospirone in the treatment of schizophrenia: Effect
on verbal memory organization
Tsuyoshi Araki, Hidenori Yamasue, Tomiki Sumiyoshi,
Hitoshi Kuwabara, Motomu Suga, Akira Iwanami, Nobumasa
Kato and Kiyoto Kasai
Genetically
predisposed offspring with schizotypal features: An
ultra high-risk group for schizophrenia?
Vaibhav A. Diwadkar, Debra M. Montrose, Diana Dworakowski, John A. Sweeney and Matcheri
S. Keshavan
Subjective
response to clozapine and risperidone
treatment in outpatients with schizophrenia
Jong-Hoon Kim, Seong-Youn Kim, Yong Min Ahn and
Yong Sik Ki
Lifetime suicide rates in treated
schizophrenia: 1875–1924 and 1994–1998 cohorts compared
D. HEALY, M. HARRIS, R. TRANTER,
P. GUTTING, R.
The British Journal of Psychiatry (2006) 188:
223-228
Comorbid
substance use and age at onset of schizophrenia
THOMAS R. E. BARNES,
The British Journal of Psychiatry (2006) 188:
237-242
Rechallenge
with clozapine following leucopenia or neutropenia during previous therapy
LOUISA R. DUNK, LINDA J. ANNAN,
CHRISTOPHER D. ANDREWS
The British Journal of Psychiatry (2006) 188:
255-263
Sudden cardiac death and antipsychotics.
Part 2: Monitoring and prevention
Nasser Abdelmawla
and Alex J. Mitchell
Advances in Psychiatric Treatment (2006) 12: 100-109
A PET
Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone
Gary Remington, David Mamo, Alain
Labelle, Jeffrey Reiss, Chekkera Shammi,
Erik Mannaert, Steve Mann, and Shitij
Kapur
American Journal of Psychiatry 163:396-401, March 2006
Negative Signs and Symptoms Secondary
to Antipsychotics: A Double-Blind, Randomized Trial
of a Single Dose of Placebo, Haloperidol, and Risperidone
in Healthy Volunteers
Juan Francisco Artaloytia,
Celso Arango, Adrienne Lahti,
Javier Sanz, Ana Pascual, Pedro Cubero, David Prieto, and
Tomás Palomo
American Journal of Psychiatry 163:488-493, March 2006
Sildenafil in the Treatment of
Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind,
Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial
Rajesh Gopalakrishnan, K.S.
Jacob, Anju Kuruvilla, B. Vasantharaj, and Jacob K. John
American Journal of Psychiatry 163:494-499, March 2006
Association of Schizophrenia and
Autoimmune Diseases: Linkage of Danish National Registers
William W. Eaton, Majella Byrne, Henrik Ewald, Ole
American Journal of Psychiatry 163:521-528, March 2006
Factor
structure and external validity of the PANSS revisited
Edwin
J.C.G. Van den Oord, Dan Rujescu,
Jaime R. Robles, Ina Giegling, Claire Birrell, József Bukszár, Lenn Murrelle,
Hans-Jürgen Möller, Lefkos Middleton and Pierandrea Muglia
Schizophrenia Research. Volume 82, Issues 2-3, 28
February 2006, Pages 213-223
Clinical
significance of sleep EEG abnormalities in chronic schizophrenia
Changkook Yang and John W. Winkelman
Schizophrenia Research. Volume 82, Issues 2-3, 28
February 2006, Pages 251-260
Augmentation Strategies of Clozapine
With Antipsychotics in the Treatment of Ultraresistant Schizophrenia
Mouaffak, Faycal; Tranulis, Constantin; Gourevitch, Raphael; Poirier,
Marie-France; Douki, Saida;
Olie, Jean-Pierre; Loo,
Henri; Gourion, David
Clinical Neuropharmacology.
29(1):28-33, January/February 2006
Concurrent Administration of Clozapine
and Electroconvulsive Therapy in Clozapine-Resistant
Schizophrenia
Havaki-Kontaxaki,
Beata J.; Ferentinos, Panayotis P.; Kontaxakis, Vassilis P.; Paplos, Konstantinos G.; Soldatos, Constantin R
Clinical Neuropharmacology.
29(1):52-56, January/February 2006
Sensorimotor Gating and Habituation of the Startle
Response in Schizophrenic Patients Randomly Treated With Amisulpride
or Olanzapine
Boris B.
Quednow, Michael Wagner, Jens Westheide,
Katrin Beckmann, Niclaas Bliesener, Wolfgang Maier and Kai-Uwe
Kühn
Biological Psychiatry. Volume 59, Issue 6, 15 March
2006, Pages 536-545
Clozapine and
Haloperidol Differentially Alter the Constitutive Activity of
Sylvia Navailles, Philippe De Deurwaerdčre and Umberto Spampinato
Biological Psychiatry. Volume 59, Issue 6, 15 March 2006,
Pages 568-575
The
cardiovascular and respiratory health of people with schizophrenia
R. Filik, A. Sipos, P. G. Kehoe, T.
Burns, S. J. Cooper, H. Stevens, R. Laugharne, G.
Young, S. Perrington, J. McKendrick,
D. Stephenson, G. Harrison
Acta Psychiatrica Scandinavica. Volume
113 Page 298 - April 2006
Recent Advances in the Treatment of
Delusional Disorder
Can J Psychiatry 2006;51:114–119
Augmentation of Clozapine With Amisulpride in
Patients With Treatment-Resistant Schizophrenia. An Open Clinical Study
Marc Ziegenbein, Marcel Sieberer, Heike E Kuenzel2, Stefan Kropp
German J Psychiatry 2006; 9: 17-21
Physical anhedonia in the
acute phase of schizophrenia
Vassilis P Kontaxakis,
Costas T Kollias, Beata J Havaki-Kontaxaki, Maria M
Margariti, Sophia S Stamouli,
Eleni Petridou, and George
N Christodoulou
Ann Gen Psychiatry. 2006; 5: 1.
Antipsychotic drugs cause glial
cell line–derived neurotrophic factor secretion from
C6 glioma cells
Zongjun Shao,
Lillian E. Dyck, Haitao
Wang, and Xin-Min Li
J Psychiatry Neurosci. 2006
January; 31(1): 32–37.
Prevalence
of diabetes mellitus in chronic schizophrenic inpatients in relation to
long-term antipsychotic treatment
D. Cohen, J.J. Dekker, J. Peen and C.C. Gispen-de
Wied
European Neuropsychopharmacology. Volume 16, Issue 3,
April 2006, Pages 187-194
Heterogeneity in Incidence Rates of Schizophrenia and
Other Psychotic Syndromes: Findings From the 3-Center ĆSOP Study
James B. Kirkbride; Paul Fearon; Craig Morgan; Paola Dazzan; Kevin Morgan; Jane
Tarrant; Tuhina Lloyd; John Holloway; Gerard Hutchinson; Julian P. Leff;
Rosemarie M. Mallett; Glynn L. Harrison; Robin M. Murray; Peter B. Jones
Arch Gen Psychiatry.
2006;63:250-258
Familial Aggregation of Eye-Tracking Endophenotypes in
Families of Schizophrenic Patients
L. Elliot Hong; Braxton D. Mitchell; Matthew T. Avila; Helene Adami; Robert P.
McMahon; Gunvant K. Thaker
Arch Gen Psychiatry.
2006;63:259-264
Adverse Events During Medical and Surgical
Hospitalizations for Persons With Schizophrenia
Gail L. Daumit; Peter J. Pronovost; Christopher B. Anthony; Eliseo Guallar;
Donald M. Steinwachs; Daniel E. Ford
Arch Gen Psychiatry. 2006;63:267-272
Neuropsychological Normalization With
Long-Term Atypical Antipsychotic Treatment: Results of a Six-Month Randomized,
Double-Blind Comparison of Ziprasidone vs. Olanzapine
Philip D. Harvey, Christopher R. Bowie, and
J Neuropsychiatry Clin Neurosci 18:54-63, February 2006
Deficit Schizophrenia: Association With
Serum Antibodies to Cytomegalovirus
Faith Dickerson, Brian Kirkpatrick, John Boronow, Cassie Stallings, Andrea Origoni
and Robert Yolken
Schizophrenia
Bulletin 2006 32(2):396-400
Hippocampal and Parahippocampal
Volumes in Schizophrenia: A Structural MRI Study
Kang Sim,, Iain
DeWitt, Tali Ditman, Martin
Zalesak, Ian Greenhouse, Donald Goff, Anthony P Weiss,
and Stephan Heckers
Schizophrenia
Bulletin 2006 32(2):332-340
Medication-Free Research in Early
Episode Schizophrenia: Evidence of Long-Term Harm?
John R Bola
Schizophrenia
Bulletin 2006 32(2):288-296
The Factorial Structure of the Schedule
for the Deficit Syndrome in Schizophrenia
David Kimhy,, Scott
Yale, Raymond R Goetz, Lynn Marcinko McFarr and Dolores Malaspina
Schizophrenia
Bulletin 2006 32(2):274-278
The Structure of Negative Symptoms
Within Schizophrenia: Implications for Assessment
Jack J Blanchard and Alex S Cohen
Schizophrenia
Bulletin 2006 32(2):238-245
Serotonergic Mechanisms in Schizophrenia: Evolution
and Current Concepts
Herbert
Y. Meltzer, Zhu Li, Mei Huang, and Adam Prus
Current Psychosis & Therapeutics Reports 2006,
4:12-19
Cholinergic Mechanisms in
Schizophrenia: Current Concepts
Thomas
J. Raedler, and Rajiv Tandon
Current Psychosis & Therapeutics Reports 2006,
4:20-34
Frequency of obsessive compulsive
symptoms and disorder in patients with schizophrenia : importence
for prognosis
A.
Üçok, R. Tükel,
G. Ozgen, M. Saylan,
G. Uzuner
L’encephale. Vol 32 - N° 1 - Février 2006; p. 41 - 44
Atypical antipsychotics
and sexual dysfunction : five case-reports associated with risperidone
L’encephale. Vol 32 - N°
1 - Février 2006; p. 97 – 105
Substance Use in Persons With
Schizophrenia: Baseline Prevalence and Correlates From the NIMH CATIE Study
Swartz, Marvin S.; Wagner, H Ryan; Swanson, Jeffrey W.;
Stroup, T Scott; McEvoy, Joseph P.; Canive, Jose M.; Miller, Del D.; Reimherr,
Fred; McGee, Mark; Khan, Ahsan; Van Dorn, Richard; Rosenheck, Robert A.;
Lieberman, Jeffrey A
Journal of Nervous & Mental Disease.
194(3):164-172, March 2006
Antipsychotic Polypharmacy:
Value for the Money?
Mark Moran
Psychiatr News March 17, 2006. Volume 41, Number 6, page 31
Metabolic risk factor profile associated
with use of second generation antipsychotics: a
cross-sectional study in a community mental health centre
BMC
Psychiatry 2006, 6:11; 16 March 2006
The hormonal environment in utero
as a potential aetiological agent for schizophrenia
M. Procopio, R. J. E. Davies and
P. Marriott
European
Archives of Psychiatry and Clinical Neuroscience 2006; Volume 256, Number
2: 77 - 81
Dorsolateral prefrontal
and superior temporal volume deficits in first–episode psychoses that evolve
into schizophrenia
V. Molina, J. Sanz, F. Sarramea, R. Luque,
C. Benito and T. Palomo
European
Archives of Psychiatry and Clinical Neuroscience 2006; Volume 256, Number
2: 106 - 111
Striatal
dopamine transporter availability is associated with the productive psychotic
state in first episode, drug–naive schizophrenic patients
G. J. E. Schmitt,
T. Frodl, S. Dresel,
C. la Fougčre, R. Bottlender,
N. Koutsouleris, K. Hahn, H.–J. Möller and E. M. Meisenzahl
European
Archives of Psychiatry and Clinical Neuroscience 2006; Volume 256, Number 2: 115 - 121
Psychoeducation
and Compliance in the Treatment of Schizophrenia: Results of the
Gabriele
Pitschel-Walz, Josef Bäuml,
Wolfram Bender, Rolf R. Engel, Michael Wagner, and Werner Kissling
J Clin Psychiatry
2006;67:443-452
Medication Adherence and Long-Term
Functional Outcomes in the Treatment of Schizophrenia in Usual Care
Haya Ascher-Svanum,
Douglas E. Faries, Baojin
Zhu, Frank R. Ernst, Marvin S. Swartz, and Jeff W. Swanson
J Clin Psychiatry
2006;67:453-460
Apoptosis in schizophrenia: pathophysiologic
and therapeutic considerations
Jarskog, L Fredrik
Current Opinion in Psychiatry. 19(3):307-312, May 2006
The "delayed
onset" of antipsychotic action — an idea whose time has come and gone
Ofer Agid, Phillip Seeman, Shitij Kapur
J Psychiatry Neurosci 2006;31(2):93-100
Treating
Auditory Hallucinations by Transcranial Magnetic
Stimulation: A Randomized Controlled Cross-Over Trial
Martin Jandl, Juergen Steyer, Martin Weber, David E.J. Linden, Johannes Rothmeier, Konrad Maurer,
Wolfgang P. Kaschka
Neuropsychobiology 2006;53:63-69
Low
Levels of 
7-Nicotinic
Acetylcholine Receptor mRNA on Peripheral Blood Lymphocytes in Schizophrenia
and Its Association with Illness Severity
Orly Perl, Rael
D. Strous, Angela Dranikov,
Rina Chen, Sara Fuchs
Neuropsychobiology 2006;53:88-93
Atypical
Antipsychotic Usage-Related Higher Serum Leptin
Levels and Disabled Lipid Profiles in Euthymic
Bipolar Patients
H. Serdar Gergerlioglu, Haluk A. Savas, Ahmet Celik, Esen
Savas, Mehmet Yumru, Mehmet Tarakcioglu,
Nursadan Gergerlioglu, Murad Atmaca
Neuropsychobiology 2006;53:108-112
What is the risk of developing parkinsonism
following neuroleptic use?
Katia Noyes, Hangsheng Liu, and Robert G. Holloway
Obsessive–compulsive
and negative symptoms in schizophrenia: Associations with coping preference and
hope
Paul H. Lysaker, Kriscinda A. Whitney and
Louanne W. Davis
Psychiatry Research. Volume 141, Issue 3, 30 March 2006, Pages
253-259
Neuropsychological
Performance Over Time in People at High Risk of Developing Schizophrenia and
Controls
Marie-Claire
Whyte, Caroline Brett, Lesley K. Harrison, Majella Byrne, Patrick Miller, Stephen M. Lawrie and Eve C. Johnstone
Biological Psychiatry. Volume 59, Issue 8, 15 April 2006, Pages
730-739
Transition rates
from schizotypal disorder to psychotic disorder for
first-contact patients included in the OPUS trial. A randomized clinical trial
of integrated treatment and standard treatment
Merete Nordentoft,
Anne Thorup, Lone Petersen, Johan Řhlenschlćger,
Marianne Melau, Torben Řstergaard Christensen, Gertrud Krarup,
Per Jřrgensen and Pia Jeppesen
Schizophrenia
Research. Volume 83, Issue 1, March 2006, Pages 29-40
Predictors of
antipsychotic medication adherence in patients recovering from a first
psychotic episode
Diana O.
Perkins, Jacqueline L. Johnson, Robert M. Hamer,
Robert B. Zipursky, Richard S. Keefe, Franca Centorrhino, Alan I. Green, Ira B. Glick, Rene S. Kahn, Tonmoy Sharma, Mauricio Tohen,
Joseph P. McEvoy, Peter J. Weiden,
Jeffrey A. Lieberman and HGDH Research Group
Schizophrenia
Research. Volume 83, Issue 1, March 2006, Pages 53-63
A 12-month prospective
follow-up study of patients with schizophrenia-spectrum disorders and substance
abuse: Changes in psychiatric symptoms and substance use
Howard
C. Margolese, Juan Carlos Negrete,
Raymond Tempier and Kathryn Gill
Schizophrenia
Research. Volume 83, Issue 1, March 2006, Pages 65-75
Prevalence of the
metabolic syndrome in patients with schizophrenia treated with antipsychotic
medication
Marc A.
De Hert, Ruud van Winkel, Dominique Van Eyck, Linda
Hanssens, Martien Wampers, Andre Scheen and Joseph Peuskens
Schizophrenia
Research. Volume 83, Issue 1, March 2006, Pages 87-93
A
cognitive/behavioral group intervention for weight loss in patients treated
with atypical antipsychotics
Mary
Weber and Kathleen Wyne
Schizophrenia
Research. Volume 83, Issue 1, March 2006, Pages 95-101
The impact of atypical antipsychotic
medications on long-term memory dysfunction in schizophrenia spectrum disorder.
A quantitative review
Allen E. Thornton, Jared X. Van Snellenberg,
Amir A. Sepehry, William Honer
Journal of Psychopharmacology, Vol. 20, No. 3, 335-346
(2006)